Complement and microglia mediate early synapse loss in Alzheimer mouse models
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index; 21 of the 28 sources its claims cite were checked for support.
Abstract
Too much cleaning up: The complement system and microglia seek out and destroy unwanted cellular debris for the peripheral immune system as well as excess synapses in the developing brain. Hong et al. now show how the system may go haywire in adults early in the progression toward Alzheimer's disease (AD). Aberrant synapse loss is an early feature of Alzheimer's and correlates with cognitive decline. In mice susceptible to AD, complement was associated with synapses, and microglial function was required for synapse loss. The authors speculate that aberrant activation of this “trash disposal” system underlies AD pathology. Science , this issue p. 712
Overview
CoChat Summary
TL;DR
In Alzheimer mouse models, classical complement proteins C1q and C3 increase and localize to synapses before plaques, and blocking C1q, C3, or microglial CR3 reduces early synapse loss. Soluble Aβ oligomers drive microglial engulfment of synaptic material through a CR3-dependent pathway, suggesting reactivation of developmental synaptic pruning in early AD.
Key findings
- J20 hAPP mice showed significant hippocampal synapse loss at 3–4 months, before plaque deposition; loss occurred in CA1, CA3, and dentate gyrus at 3 months but not in striatum, and was not seen at 1 month.
- C1q was elevated in J20 brains as early as 1 month, region-specifically in hippocampus and frontal cortex, and colocalized with PSD95-positive puncta; Compound E reduced soluble Aβ and C1q deposition, while oligomeric Aβ—but not monomeric Aβ or vehicle—induced C1q deposition and synaptic colocalization.
- Oligomeric Aβ induced synapse loss within 72 h in WT mice but not in C1qa knockout mice; anti-C1q antibody ANX-M1 prevented oAβ-induced synapse loss and LTP impairment, and APP/PS1xC3 KO mice did not show the synapse loss seen in 4-month APP/PS1 hippocampus.
- Microglial CD68 increased in J20 hippocampus and after oAβ; oAβ increased internalized Homer-GFP in microglia, failed to do so in CR3 KO mice, and induced hippocampal synapse loss in WT but not CR3 KO mice.
Methods
- Mouse models included J20 hAPP, APP/PS1, C1qa KO, C3 KO, CR3 KO, and Homer-GFP mice, with WT littermates and ages including 1 month, 3–4 months, and P21.
- Synapse quantification used super-resolution structured illumination microscopy, confocal imaging, and electron microscopy with colocalized pre- and postsynaptic puncta markers including synaptophysin/PSD95, synaptotagmin/homer, and synapsin/PSD95; C1q and C3 colocalization with PSD95 was also measured.
- Interventions included Compound E, intracerebroventricular or tail vein injections of soluble Aβ oligomers, monomers, or vehicle, anti-C1q antibody ANX-M1 or IgG control, acute hippocampal slice LTP recordings, and an in vivo synaptic engulfment assay.
Limitations
- The paper states that specific synaptic C1q receptors are not yet known and that oAβ and C1q may act indirectly through cytokines such as TGFβ, microglial or astrocytic activation, or other pathways including MHCI/PirB.
- The paper states that the complement pathway may not be involved in all pathological routes to AD, including plaque-associated synapse loss, and that future studies are needed to examine plaque-associated synapse loss and other synaptopathies such as tauopathies and Huntington’s disease.
- Evident from the text: the findings are from mouse models and acute hippocampal slices, not human AD tissue or clinical trials, and the study focuses on early pre-plaque mechanisms rather than established plaque-associated neuropathology.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 0 Not valid · 2 Not checked · 48 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“C1q binds synapses in vulnerable regions undergoing synapse loss (our data here; (5, 27)).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [5] Stevens B The classical complement cascade mediates CNS synapse elimination. Cell 2007 131 1164 1178 18083105 source
The Results report C1q localized to synapses in the developing dLGN during synaptic pruning and relocalized to adult retinal synapses in early glaucoma, before significant synapse loss. The Discussion likewise places synaptic C1q relocalization before or concurrent with synapse loss in the glaucoma model. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [27] Stephan AH Barres BA Stevens B The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci 2012 35 369 389 22715882 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that the engulfed synapses are internalized into lysosomal compartments in a manner similar to developmental synaptic pruning (6).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [6] Schafer DP Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. Neuron 2012 74 691 705 22632727 PMC3528177 source
The Results section, “Microglia engulf RGC inputs during a period of active synaptic pruning” (page unavailable), reports that most engulfed RGC inputs colocalized with microglial lysosomal compartments. The Results section, “Microglia engulf presynaptic elements specific to RGCs” (page unavailable), also identifies an RGC presynaptic marker within microglial lysosomes, supporting the proposed similarity to developmental synaptic pruning. (LLM, conf=0.94)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Quantification of colocalized pre- and postsynaptic puncta (synaptophysin and PSD95 (Fig. 1A); synaptotagmin and homer (figs. S1A-D)) revealed a significant loss of synapses in J20 hippocampus at 3-4 months old (mo), an age that precedes plaque deposition (11, 12).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [11] Mucke L High-Level Neuronal Expression of Abeta 1-42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation. Journal of Neuroscience 2000 20 4050 10818140 PMC6772621 source
The citation is attached to the statement that 3–4 months precedes plaque deposition, not to the citing authors’ synapse measurements. In “Effects of hAPP mutations on formation of amyloid plaques” (Fig. 4; page not provided), the paper assesses mice at 2–4 months and reports amyloid deposition in APP Sw,Ind mice at 5–7 months; the paper identifies J20 as an APP Sw,Ind line. (LLM, conf=0.91)
- Supportedcites [12] Hong S Dynamic Analysis of Amyloid -Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal A during Age-Related Plaque Formation. Journal of Neuroscience 2011 31 15861 15869 22049429 PMC3227224 source
The citation follows the statement that 3–4 months precedes plaque deposition, rather than the citing authors’ own synapse measurements. The Results section (page unavailable) identifies approximately 3-month-old J20 mice as pre-plaque and describes 3–7-month-old mice as plaque-free. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genome-wide association studies (GWAS) implicate microglia and complement-related pathways in AD (1).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [1] Hong S Dissing-Olesen L Stevens B New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol 2016 doi:10.1016/j.conb.2015.12.004 PMC5479435 26745839 source
The Introduction says GWAS and integrated network studies identify immune-related AD risk pathways implicating microglia. The section on microglia–synapse dysfunction identifies GWAS variants CLU and CR1, both related to complement. Page numbers are not provided in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“C1q was also similarly increased in hippocampus of another model of AD, the APP/PS1 mice (15) (Fig. S2C).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [15] Jankowsky JL Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet 2004 13 159 170 14645205 source
The citation identifies the APP/PS1 mouse model, while the citing document points to its own Fig. S2C for the C1q increase. Figure 2 (p. 4) describes APPswe/PS1 double-transgenic mice and shows hippocampal amyloid pathology in that model. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
48 more claims · 5 with their cited sources checked
Create a free account to see all 66 claims and every source verdict.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“increasing evidence demonstrate that immune signaling may not just be a consequence of protein aggregation in the brain, but that it actually causes the buildup of aggregates at the earliest stages of the disease process.15–17”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [15]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In neurodegeneration, the complement pathway is activated, and inhibiting the complement proteins C1q or C3 results in less neuroinflammation, Aβ plaques and synapse loss29,30.”
From Exercise plasma boosts memory and dampens brain inflammation via clusterin (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Before the onset of Aβ deposition, microglia engulf synapses opsonized with the complement factors C1q and C3 upon CR3-mediated recognition of C3 (121).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lack of C1q, C3, or CR3 curbed microglia activation and synaptic loss during amyloid plaque deposition.”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [139]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inappropriate control of the classical complement cascade causes unresolvable inflammation and disease (Hong et al. , 2016; Hansen, Hanson and Sheng, 2018; Morgan, 2018).”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Hong et al., 2016
Experimental — accuracy not yet measured
70 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“It is also plausible that oAβ and C1q may work indirectly to mediate synapse loss through cytokines such as TGFβ (7), through microglial or astrocytic activation, or through other mechanisms including MHCI/PirB, another immune pathway critical for synapse elimination in development and AD (28-30).”
Cited work 10.1038/nn.3560 · retracted 2022-01-13 · notice 10.1038/s41593-021-00877-7 · this paper published 2016-05-06
Citations
Cites
1 retracted
Bialas, A. R., & Stevens, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3560 · Cited by 519 · cited 2×
“It is also plausible that oAβ and C1q may work indirectly to mediate synapse loss through cytokines such as TGFβ (7), through microglial or astrocytic activation, or through other mechanisms including MHCI/PirB, another immune pathway critical for synapse elimination in development and AD (28-30).”
Self-citationRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“Synaptic deficits occur in early AD and mild cognitively impaired patients before onset of plaques and are some of the first signs of the neuronal degenerative process (4, 23-25).”
Self-citationTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“The degree of region-specific synapse loss is a stronger correlate of cognitive decline in AD than counts of plaques, tangles and neuronal loss (8, 9).”
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Self-citationThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313 · cited 4×
“Although specific receptors for C1q at synapses are not yet known, C1q binds synapses in vulnerable regions undergoing synapse loss (our data here; (5, 27)).”
InfluentialSelf-citationIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“S11), indicating they are resident cells (22).”
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · cited 1×
“The degree of region-specific synapse loss is a stronger correlate of cognitive decline in AD than counts of plaques, tangles and neuronal loss (8, 9).”
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 3×
“S4), long before Aβ plaques deposit (11, 12), raising the question of whether C1q increase in these pre-plaque brains is dependent on soluble Aβ levels.”
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Cited by
Items 301–400 of 3,349
Moreno, L. C. G. E. I., Puerta, E., Suárez-Santiago, J. E., Santos-Magalhães, N. S., Ramirez, M. J., & Irache, J. M. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.11.061 · Cited by 170
Zhong, L., Sheng, X., Wang, W., Li, Y., Zhuo, R., Wang, K., Zhang, L., Hu, D.-D., Hong, Y., Chen, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.016 · Cited by 168
Dourlen, P., Kilinc, D., Malmanche, N., Chapuis, J., & Lambert, J.-C. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02004-0 · Cited by 168
“It is also suspected that perturbations in homeostatic microglia functions at synapses may lead to early synapse loss in an Aβ-dependent or potentially independent manner [52, 93].”
BackgroundMammana, S., Fagone, P., Cavalli, E., Basile, M., Petralia, M., Nicoletti, F., Bramanti, P., & Mazzon, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030831 · Cited by 166
“The signaling pathway CR3/C3 has also recently been implicated in early synapse loss in mouse models of AD-like pathology, suggesting that inappropriate activation of microglia by pathogenic proteins results in aberrant phagocytosis of functional synapses [92].”
BackgroundCell type-specific inference of differential expression in spatial transcriptomics
Cable, D. M., Murray, E., Shanmugam, V., Zhang, S., Zou, L. S., Diao, M., Chen, H., Macosko, E. Z., Irizarry, R. A., & Chen, F. (2022) · Nature Methods · doi:10.1038/s41592-022-01575-3 · Cited by 164
“85, P = 1 × 10 − 4 ), which is involved in plaque-associated synaptic pruning in Alzheimer’s disease 33–35 .”
BackgroundResultLiu, Q., Sun, Y.-M., Huang, H., Chen, C., Wan, J., Ma, L.-H., Sun, Y.-Y., Miao, H.-H., & Wu, Y.-Q. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02089-z · Cited by 165
“Microglial synaptic pruning contributes to neuronal network establishment [50].”
BackgroundNeuron–Microglia Interactions in Mental Health Disorders: “For Better, and For Worse”
Wohleb, E. S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00544 · Cited by 163
“This is plausible as synapse loss is a common pathophysiological feature observed in depressed individuals and early stages of neurodegenerative diseases (141, 142).”
BackgroundBrains and Brawn: Toxoplasma Infections of the Central Nervous System and Skeletal Muscle
Wohlfert, E. A., Blader, I. J., & Wilson, E. H. (2017) · Trends in Parasitology · doi:10.1016/j.pt.2017.04.001 · Cited by 164
Lu, Y., Guo, Z., Zhang, Y., Li, C., Zhang, Y., Guo, Q., Chen, Q., Chen, X., He, X., Liu, L., et al. (2019) · Advanced Science · doi:10.1002/advs.201801586 · Cited by 164
Comer, A. L., Jinadasa, T., Sriram, B., Phadke, R. A., Kretsge, L. N., Nguyen, T. P. H., Antognetti, G., Gilbert, J. P., Lee, J., Newmark, E. R., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000604 · Cited by 163
Molecular Mechanisms of Neuroinflammation in Aging and Alzheimer’s Disease Progression
Andronie-Cioara, F. L., Ardelean, A. I., Nistor-Cseppento, C. D., Jurcau, A., Jurcau, M. C., Pascalau, N., & Marcu, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031869 · Cited by 164
Litvinchuk, A., Suh, J. H., Guo, J. L., Lin, K., Davis, S. S., Bien-Ly, N., Tycksen, E., Tabor, G. T., Remolina Serrano, J., Manis, M., et al. (2024) · Neuron · doi:10.1016/j.neuron.2023.10.023 · Cited by 161
Innate immune activation in neurodegenerative diseases
Castro-Gomez, S., & Heneka, M. T. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.010 · Cited by 162
Ubiquitin Ligase COP1 Suppresses Neuroinflammation by Degrading c/EBPβ in Microglia
Ndoja, A., Reja, R., Lee, S.-H., Webster, J. D., Ngu, H., Rose, C. M., Kirkpatrick, D. S., Modrusan, Z., Chen, Y.-J. J., Dugger, D. L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.011 · Cited by 159
Sen, M. K., Mahns, D. A., Coorssen, J. R., & Shortland, P. J. (2022) · Glia · doi:10.1002/glia.24148 · Cited by 159
Zhou, X., Dong, K., & Zhang, S. (2023) · Nature Computational Science · doi:10.1038/s43588-023-00528-w · Cited by 160
“STA-ligner captured the known brain tissue structures of the olfactory bulb (domains 3, 17, 37), cortex (domains 6, 9, 10, 16, 20, 33, 35), stratium (domains 2, 12, 34), thalamus (domains 4, 24, 27, 30), hypothalamus (domains 5, 7, 28), hippocampus (domains 14, 19, 31, 36), cerebellum (domains 8,…”
Chronic Stress Weakens Connectivity in the Prefrontal Cortex: Architectural and Molecular Changes.
Woo, E., Sansing, L. H., Arnsten, A. F. T., & Datta, D. (2021) · Chronic Stress · doi:10.1177/24705470211029254 · Cited by 159
Astrocytes and the TGF-β1 Pathway in the Healthy and Diseased Brain: a Double-Edged Sword
Diniz, L. P., Matias, I., Siqueira, M., Stipursky, J., & Gomes, F. C. A. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1396-y · Cited by 159
Grimaldi, A., Pediconi, N., Oieni, F., Pizzarelli, R., Rosito, M., Giubettini, M., Santini, T., Limatola, C., Ruocco, G., Ragozzino, D., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00925 · Cited by 157
Haure-Mirande, J.-V., Audrain, M., Ehrlich, M. E., & Gandy, S. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00552-w · Cited by 159
“This decrease is associated with the maintenance of normal learning behavior and electrophysiological properties, supporting suggestions from others that C1q is a target of interest in the treatment of neurodegenerative diseases [11, 18].”
BackgroundCastillo, E., Leon, J., Mazzei, G., Abolhassani, N., Haruyama, N., Saito, T., Saido, T., Hokama, M., Iwaki, T., Ohara, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17999-3 · Cited by 158
Xie, M., Liu, Y. U., Zhao, S., Zhang, L., Bosco, D. B., Pang, Y.-P., Zhong, J., Sheth, U., Martens, Y. A., Zhao, N., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00975-6 · Cited by 157
“In addition, other receptors like complement receptors, P2Y6 and TAM receptors are also involved in microglial phagocytosis 37–39 .”
Targeting synapse function and loss for treatment of neurodegenerative diseases
Dejanovic, B., Sheng, M., & Hanson, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00823-1 · Cited by 194
“Treatment with C1q-blocking antibodies, often delivered directly to the CNS, is sufficient to reduce microglial synapse elimination and rescue synapse density in amyloidosis and tauopathy mouse models 19,25 .”
Chung, H.-Y., Wickel, J., Hahn, N., Mein, N., Schwarzbrunn, M., Koch, P., Ceanga, M., Haselmann, H., Baade-Büttner, C., von Stackelberg, N., et al. (2023) · Science Advances · doi:10.1126/sciadv.abq7806 · Cited by 156
“Therefore, it is mandatory that complement inhibition is restricted to the CNS compartment, and established C1q-blocking antibody application protocols ( 34 , 40 , 50 ) cannot be used in the PCI model to test a direct therapeutic effect on cognitive behavior.”
Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors
Sellgren, C. M., Sheridan, S. D., Gracias, J., Xuan, D., Fu, T., & Perlis, R. H. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.220 · Cited by 156
CSF1R antagonism limits local restimulation of antiviral CD8+ T cells during viral encephalitis
Funk, K. E., & Klein, R. S. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1397-4 · Cited by 156
“We and others have reported that microglia impact neurocognitive function by executing complement-mediated synapse elimination [8, 74, 75] .”
The synapse as a treatment avenue for Alzheimer’s Disease
Peng, L., Bestard‐Lorigados, I., & Song, W. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01565-z · Cited by 180
“Similarly, Aβ oligomer treatment did not cause synaptic dysfunction in C1q-KO mice [63].”
BackgroundOksanen, M., Lehtonen, S., Jaronen, M., Goldsteins, G., Hämäläinen, R. H., & Koistinaho, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03111-7 · Cited by 153
“1 3 unclear, although several theories involving beta-amyloid (Aβ) plaques, complement cascade pathway, and microglia have been proposed [15] [16].”
BackgroundZhou, J., Wade, S. D., Graykowski, D., Xiao, M.-F., Zhao, B., Giannini, L. A. A., Hanson, J. E., van Swieten, J. C., Sheng, M., Worley, P. F., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf0141 · Cited by 152
“Blocking C1q binding to neurons is sufficient to attenuate synapse loss in mouse models of AD, FTD, and Huntington’s disease (7, 11, 13).”
BackgroundCai, Q., Li, Y., & Pei, G. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0839-0 · Cited by 168
“Deficit in C1q results into an increased number of synapses and provides a neuroprotective function [31, 55].”
InfluentialFunctional dissection of astrocyte-secreted proteins: Implications in brain health and diseases
Jha, M. K., Kim, J.-H., Song, G. J., Lee, W., Lee, I. K., Lee, H., An, S. S. A., Kim, S., & Suk, K. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.003 · Cited by 167
“In AD mouse models, Hong et al. (2016) have recently reported that complement and microglia mediate the early synaptic loss and dysfunction that occur in AD models before plaques form (Hong et al., 2016).”
BackgroundWitcher, K. G., Bray, C. E., Dziabis, J. E., McKim, D. B., Benner, B. N., Rowe, R. K., Kokiko‐Cochran, O. N., Popovich, P. G., Lifshitz, J., Eiferman, D. S., et al. (2018) · Glia · doi:10.1002/glia.23523 · Cited by 151
“, 2017; Prinz & Priller, 2014) and microglia have CNS-specific and conserved responses to neuronal injury and neurodegeneration (Hong et al., 2016; Krasemann et al., 2017).”
BackgroundRetinal pathological features and proteome signatures of Alzheimer’s disease
Koronyo, Y., Rentsendorj, A., Mirzaei, N., Regis, G. C., Sheyn, J., Shi, H., Barrón, E., Cook‐Wiens, G., Rodriguez, A., Medeiros, R., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02548-2 · Cited by 169
Astrocytes decrease adult neurogenesis during virus-induced memory dysfunction via IL-1
Garber, C., Vasek, M. J., Vollmer, L. L., Sun, T., Jiang, X., & Klein, R. S. (2018) · Nature Immunology · doi:10.1038/s41590-017-0021-y · Cited by 151
“Complement-mediated synapse elimination has been reported to occur in numerous neuroinflammatory diseases, including multiple sclerosis 18 , Alzheimer’s disease 19 , and schizophrenia 20 , suggesting this may be a general mechanism underlying inflammation-associated disruption of neural circuitry.”
Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis
Wang, J., Wang, J., Wang, J., Yang, B., Weng, Q., & He, Q. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00286 · Cited by 147
PSD-95 protects synapses from β-amyloid
Dore, K., Carrico, Z., Alfonso, S., Marino, M., Koymans, K., Kessels, H. W., & Malinow, R. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109194 · Cited by 149
“Furthermore, reduced levels of PSD-95 are seen in AD model mice (Hong et al., 2016; Shao et al., 2011) and brains of patients with AD (Perez-Nievas et al.”
BackgroundRezaei Asl, Z., Sepehri, G., & Salami, M. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112183 · Cited by 149
Single-Cell RNA Sequencing of Peripheral Blood Reveals Immune Cell Signatures in Alzheimer’s Disease
Xu, H., & Jia, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645666 · Cited by 149
“In the CNS, microglia, the most important immune cells in the nervous microenvironment, can convert to an activated state to phagocytize and remove amyloid beta (Aß), and they promote the release of inflammatory cytokines, thus accelerating neuronal damage (4).”
BackgroundXu, C., Wu, J. S., Wu, Y., Ren, Z., Yao, Y., Chen, G., Fang, E. F., Noh, J. H., Liu, Y., Wei, L., et al. (2021) · Theranostics · doi:10.7150/thno.62376 · Cited by 158
“Among the various forms of cell death pathways, while it is still debating the role of neuronal apoptosis in AD, increased necrosis and microglial phagocytosis are likely playing important roles in neuronal death in AD [8-10].”
BackgroundInsights into Alzheimer’s disease from single-cell genomic approaches
Murdock, M. H., & Tsai, L.-H. (2023) · Nature Neuroscience · doi:10.1038/s41593-022-01222-2 · Cited by 148
Mottahedin, A., Ardalan, M., Chumak, T., Riebe, I., Ek, J., & Mallard, C. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00190 · Cited by 147
“Microglia cells have also been shown to be responsible for the early synapse loss in mouse models of AD in a complement-dependent manner (Hong et al., 2016).”
BackgroundAdvances in the Potential Biomarkers of Epilepsy
Kobylarek, D., Iwanowski, P., Lewandowska, Z., Limphaibool, N., Szafranek, S., Labrzycka, A., & Kozubski, W. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00685 · Cited by 148
“Recent studies have shown new non-canonical roles for phagocytic C1q-C3 signals in improving synaptic connectivity (96, 97).”
BackgroundSchafer, D. P., Heller, C. T., Gunner, G., Heller, M., Gordon, C., Hammond, T., Wolf, Y., Jung, S., & Stevens, B. (2016) · eLife · doi:10.7554/elife.15224 · Cited by 147
Self-citationTzioras, M., Davies, C., Newman, A., Jackson, R., & Spires‐Jones, T. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12529 · Cited by 147
Microglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets
Nizami, S., Hall‐Roberts, H., Warrier, S., Cowley, S. A., & Di Daniel, E. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14618 · Cited by 147
“This process has not been fully delineated in adult neurodegenerative disease brains, but a strong link has been confirmed between C1q/C3 and synapse loss in AD mice (Hong et al., 2016).”
BackgroundGlial cells in Alzheimer’s disease: From neuropathological changes to therapeutic implications
Uddin, M. S., & Lim, L. W. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101622 · Cited by 145
Xie, J., Cools, L., Van Imschoot, G., Van Wonterghem, E., Pauwels, M. J., Vlaeminck, I., De Witte, C., EL Andaloussi, S., Wierda, K., De Groef, L., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12306 · Cited by 149
“molecules are expressed in the CNS where they have been implicated in AD processes (Chen et al., 2020; Hong et al., 2016).”
BackgroundC9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation
Lall, D., Lorenzini, I., Mota, T. A., Bell, S., Mahan, T. E., Ulrich, J. D., Davtyan, H., Rexach, J. E., Muhammad, A. K. M. G., Shelest, O., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.05.020 · Cited by 147
Millan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 153
Enteric nervous system manifestations of neurodegenerative disease
Chalazonitis, A., & Rao, M. (2018) · Brain Research · doi:10.1016/j.brainres.2018.01.011 · Cited by 145
Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors
Nestor, J., Arinuma, Y., Huerta, T. S., Kowal, C., Nasiri, E., Kello, N., Fujieda, Y., Bialas, A., Hammond, T., Sriram, U., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180776 · Cited by 146
“Recent studies have shown microglia-mediated synaptic loss in the hippocampus in a mouse model of Alzheimer’s disease (AD) in which amyloid is injected into the brain; dendritic loss can be blocked by the administration of anti-C1q antibody (Hong et al., 2016).”
BackgroundMethodZhuang, H., Yao, X., Li, H., Li, Q., Yang, C., Wang, C., Xu, D., Xiao, Y., Gao, Y. J., Gao, J., et al. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.11.018 · Cited by 162
Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease
Wang, M., Zhang, H., Liang, J., Huang, J., & Chen, N. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02753-6 · Cited by 162
Astrocytes, Microglia, and Parkinson’s Disease
Joe, E.-H., Choi, D.-J., An, J., Eun, J.-H., Jou, I., & Park, S. (2018) · Experimental Neurobiology · doi:10.5607/en.2018.27.2.77 · Cited by 144
Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration
Henstridge, C. M., Tzioras, M., & Paolicelli, R. C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00063 · Cited by 143
Fast-spiking parvalbumin-positive interneurons in brain physiology and Alzheimer’s disease
Hijazi, S., Smit, A. B., & van Kesteren, R. E. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02168-y · Cited by 163
“Several studies have reported a microglia-dependent loss of synapses is early in AD, leading to neurode-generation and memory loss [191 – 193].”
BackgroundChen, S., Chang, Y., Li, L., Acosta, D., Li, Y., Guo, Q., Wang, C., Turkes, E., Morrison, C., Julian, D., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01494-6 · Cited by 144
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial
van Dyck, C. H., Nygaard, H. B., Chen, K., Donohue, M. C., Raman, R., Rissman, R. A., Brewer, J. B., Koeppe, R. A., Chow, T. W., Rafii, M. S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2050 · Cited by 142
Hao, W., Ma, Q., Wang, L., Yuan, N., Gan, H., He, L., Li, X., Huang, J., & Chen, J. (2024) · Microbiome · doi:10.1186/s40168-024-01756-6 · Cited by 143
“Recent research has revealed that complement is involved in developmental synaptic pruning and pathological synapse loss, the latter of which contributes to various brain diseases including schizophrenia, depression, autism, and anxiety disorders [10, 11].”
BackgroundMicroglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity
Czirr, E., Castello, N. A., Mosher, K. I., Castellano, J. M., Hinkson, I. V., Lucin, K. M., Baeza-Raja, B., Ryu, J. K., Li, L., Farina, S. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162011 · Cited by 126
Dysregulation of Cortical Neuron DNA Methylation Profile in Autism Spectrum Disorder
Nardone, S., Sams, D. S., Zito, A., Reuveni, E., & Elliott, E. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx250 · Cited by 137
“…level, have already been identified in several psychiatric disorders including Schizophrenia (Ripke et al. 2014; Sekar et al. 2016), Alzheimer (Hong et al. 2016) and, recently, also in ASD by transcriptomic and epigenomic post-mortem brain studies (Voineagu et al. 2011; Gupta et al. 2014;…”
BackgroundInfluentialKrukowski, K., Chou, A., Feng, X., Tiret, B., Paladini, M.-S., Riparip, L.-K., Chaumeil, M. M., Lemere, C., & Rosi, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123753 · Cited by 141
“Beginning immediately after TBI surgery, aged, male animals received intraperitoneal injections of an inhibitory antibody against C1q (ANX-M1, Annexon Biosciences, South San Francisco, CA, USA or an isotype-matched control antibody (mouse immunoglobulin G1 (IgG1), BD Pharmingen, San Diego, CA, USA) [16].”
BackgroundMethodInfluentialSelf-citationSialylation and Galectin-3 in Microglia-Mediated Neuroinflammation and Neurodegeneration
Puigdellívol, M., Allendorf, D. H., & Brown, G. C. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00162 · Cited by 141
“, 2018; Rajendran and Paolicelli, 2018) and complement-mediated microglial phagocytosis of synapses is aberrantly activated and contributes to synaptic loss in mouse models of Alzheimer’s disease (AD) (Stevens et al., 2007; Schafer and Stevens, 2010; Hong et al., 2016).”
BackgroundEwers, M., Biechele, G., Suárez‐Calvet, M., Sacher, C., Blume, T., Morenas‐Rodriguez, E., Deming, Y., Piccio, L., Cruchaga, C., Kleinberger, G., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012308 · Cited by 133
“However, microglia activation can also be detrimental by inducing neurotoxic inflammation (Meda et al, 1995; Hong et al, 2016).”
BackgroundA unifying hypothesis for Alzheimer's disease: from plaques to neurodegeneration
Edwards, F. A. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.03.003 · Cited by 140
“Note that the 186 engulfment of synapses by microglia around plaques has been clearly demonstrated in other 187 studies[44].”
BackgroundResultMirzaei, M., Gupta, V. B., Chick, J. M., Greco, T. M., Wu, Y., Chitranshi, N., Wall, R. V., Hone, E., Deng, L., Dheer, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12858-7 · Cited by 139
Henstridge, C. M., Sideris, D. I., Carroll, E., Rotariu, S., Salomonsson, S., Tzioras, M., McKenzie, C.-A., Smith, C., von Arnim, C. A. F., Ludolph, A. C., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1797-4 · Cited by 135
Meningeal inflammation and cortical demyelination in acute multiple sclerosis
Bevan, R. J., Evans, R., Griffiths, L., Watkins, L. M., Rees, M. I., Magliozzi, R., Allen, I., McDonnell, G., Kee, R., Naughton, M., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25365 · Cited by 139
Evolution of neuroinflammation across the lifespan of individuals with Down syndrome
Flores-Aguilar, L., Iulita, M. F., Kovecses, O., Torres, M. D., Levi, S. M., Zhang, Y., Askenazi, M., Wisniewski, T., Busciglio, J., & Cuello, A. C. (2020) · Brain · doi:10.1093/brain/awaa326 · Cited by 138
“Such response is primarily characterized by neuronal upregulation of inflammatory markers and intermediate activation of microglia (Janelsins et al., 2005; Ferretti et al., 2012; Hanzel et al., 2014; Hong et al., 2016; Welikovitch et al., 2020).”
BackgroundGlutamatergic synaptic plasticity and dysfunction in Alzheimer disease: Emerging mechanisms
Benarroch, E. E. (2018) · Neurology · doi:10.1212/wnl.0000000000005807 · Cited by 115
“Microglia express the complement receptor CR3 that is activated by C1q associated with senescent synapses; this increases the number of phagocytic microglia and thereby promotes synaptic pruning.(88)”
BackgroundFunctional and structural damage of neurons by innate immune mechanisms during neurodegeneration
Ising, C., & Heneka, M. T. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0153-x · Cited by 128
The amyloid plaque proteome in early onset Alzheimer’s disease and Down syndrome
Drummond, E., Kavanagh, T., Pires, G., Marta-Ariza, M., Kanshin, E., Nayak, S., Faustin, A., Berdah, V., Ueberheide, B., & Wisniewski, T. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01356-1 · Cited by 137
“9 Yes [92] Increased Increases pathology [94, 99, 100]”
BackgroundInfluentialThe immune system and psychiatric disease: a basic science perspective
Bennett, F. C., & Molofsky, A. V. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13334 · Cited by 137
Research Progress in the Pathogenesis of Alzheimer's Disease
Chen, Y.-G. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.235112 · Cited by 136
“Meanwhile, it was ago taken for that synaptic loss was the secondary change of protein denaturation, but the research of Hong et al.[21] found that at the beginning of the AD cynapses could be already reduced and the decrease maybe is anterior to the formation of plaques, but from the abnormal of synaptic pruning mech…”
ResultMicroglia in Alzheimer's Disease: Risk Factors and Inflammation
Katsumoto, A., Takeuchi, H., Takahashi, K., & Tanaka, F. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00978 · Cited by 136
“A recent study revealed that upregulation of complement C1q and C3 promotes synapse loss by microglial phagocytosis in AD (53).”
BackgroundAlzheimer’s disease-associated (hydroxy)methylomic changes in the brain and blood
Lardenoije, R., Roubroeks, J. A. Y., Pishva, E., Leber, M., Wagner, H., Iatrou, A., Smith, A. R., Smith, R. G., Eijssen, L. M. T., Kleineidam, L., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0755-5 · Cited by 135
“C3 has previously been implicated in mediating synaptic loss in the early stages of AD [23].”
BackgroundBrelstaff, J. H., Mason, M., Katsinelos, T., McEwan, W. A., Ghetti, B., Tolkovsky, A. M., & Spillantini, M. G. (2021) · Science Advances · doi:10.1126/sciadv.abg4980 · Cited by 135
“that microglia are capable of aberrantly phagocytosing synapses and viable neurons in the adult mouse brain (15-17) and this may be increased in Alzheimer’s disease and frontotemporal dementia (18, 19).”
Transcriptional and Epigenetic Regulation of Microglia in Health and Disease
Yeh, H., & Ikezu, T. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.004 · Cited by 135
Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy
Clayton, K. A., Van Enoo, A. A., & Ikezu, T. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00680 · Cited by 134
“Recently, one study has found that synaptic pruning is negatively altered in disease conditions and results in microglia-mediated synaptic loss (Hong et al., 2016).”
BackgroundCX3CR1+ monocytes modulate learning and learning-dependent dendritic spine remodeling via TNF-α
Garré, J. M., Silva, H. M., Lafaille, J. J., & Yang, G. (2017) · Nature Medicine · doi:10.1038/nm.4340 · Cited by 132
“Previous studies have shown that microglia are important for synapse formation and elimination under both physiological and pathological conditions 35, 36, 37 .”
SARS-CoV-2 Infects Neurons and Induces Neuroinflammation in a Non-Human Primate Model of COVID-19
Beckman, D., Bonillas, A. C., Diniz, G. B., Ott, S. P., Roh, J. W., Elizaldi, S. R., Schmidt, B., Sammak, R. L., Rompay, K. K. A. V., Iyer, S. S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111573 · Cited by 141
Microglia-driven regulation of oligodendrocyte lineage cells, myelination, and remyelination
Miron, V. E. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri1116-494r · Cited by 134
Distinct cytokine profiles in human brains resilient to Alzheimer's pathology
Barroeta-Espar, I., Weinstock, L. D., Perez-Nievas, B. G., Meltzer, A. C., Siao Tick Chong, M., Amaral, A. C., Murray, M. E., Moulder, K. L., Morris, J. C., Cairns, N. J., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.10.009 · Cited by 133
Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer’s disease
Xiong, F., Ge, W., & Ma, C. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.10.006 · Cited by 133
“Recent studies using a C3-deficient mouse model have highlighted the role of C3 in clearing Ab and eliminating synapses during the progression of AD [40,41].”
BackgroundComplement factor C1q mediates sleep spindle loss and epileptic spikes after mild brain injury
Holden, S. S., Grandi, F. C., Aboubakr, O., Higashikubo, B., Cho, F. S., Chang, A. H., Forero, A. O., Morningstar, A. R., Mathur, V., Kuhn, L. J., et al. (2021) · Science · doi:10.1126/science.abj2685 · Cited by 133
“Amaladaptive role of C1q, including aberrant synapse loss, has been reported in an in vivo mouse model of Alzheimer’s disease (22), although other studies have shown that C1q can also play a “beneficial” role in Alzheimer’s disease by preventing the neurotoxicity caused by amyloid-b (51, 52).”
MethodResult3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
Choi, S. H., Kim, Y. H., Quinti, L., Tanzi, R. E., & Kim, D. Y. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0139-7 · Cited by 132
Inflammasomes as therapeutic targets for Alzheimer's disease
White, C. S., Lawrence, C. B., Brough, D., & Rivers‐Auty, J. (2017) · Brain Pathology · doi:10.1111/bpa.12478 · Cited by 130
“gene (20); and gene variants of the complement receptor 1 (CR1), which may be integral to the phagocytosis of opsonized amyloid oligomers (62).”
BackgroundPET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
“Further, recent preclinical evidence pointed to the contribution of immunoreaction to early synapse loss in rodent models of AD [38].”
BackgroundSelf-citationMicroglia-Mediated Neuroprotection, TREM2, and Alzheimer’s Disease: Evidence From Optical Imaging
Condello, C., Yuan, P., & Grutzendler, J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.007 · Cited by 131
“However, chronic microglial activation may be associated with production of neurotoxic inflammatory cytokines and reactive oxygen species (31), and microglia have been suggested to phagocytose synapses under pathological conditions (32,33); therefore, they could exert deleterious effects that contribute to disease pat…”
β-Amyloid and the Pathomechanisms of Alzheimer’s Disease: A Comprehensive View
Penke, B., Bogár, F., & Fülöp, L. (2017) · Molecules · doi:10.3390/molecules22101692 · Cited by 132
“Contrary, novel experiments have demonstrated that microglia mediate synaptic loss in an early-AD mouse model [251].”
ResultNazmi, A., Field, R. H., Griffin, E. W., Haugh, O., Hennessy, E., Cox, D., Reis, R., Tortorelli, L., Murray, C. L., Lopez‐Rodriguez, A. B., et al. (2019) · Glia · doi:10.1002/glia.23592 · Cited by 130
“There is evidence for a role for complement-mediated opsonization of synaptic elements in models of AD (Hong et al., 2016; Stevens et al., 2007), and activation of phagocytic and lysosomal pathways is conserved across multiple neurodegenerative diseases (Holtman et al.”
BackgroundMicroglia Control Escalation of Drinking in Alcohol-Dependent Mice: Genomic and Synaptic Drivers
Warden, A. S., Wolfe, S. A., Khom, S., Varodayan, F. P., Patel, R. R., Steinman, M. Q., Bajo, M., Montgomery, S. E., Vlkolinsky, R., Nadav, T., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.05.011 · Cited by 127
“This dysregulation produces abnormal synaptic engulfment (4), loss of blood-brain-barrier integrity (5), peripheral immune cell recruitment (5) and chronic immune activation (6).”
BackgroundTransgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis
Sanchez-Varo, R., Mejias-Ortega, M., Fernandez-Valenzuela, J. J., Nuñez-Diaz, C., Caceres-Palomo, L., Vegas-Gomez, L., Sanchez-Mejias, E., Trujillo-Estrada, L., Garcia-Leon, J. A., Moreno-Gonzalez, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105404 · Cited by 129
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129
Complement dysregulation in the central nervous system during development and disease
Lee, J. D., Coulthard, L. G., & Woodruff, T. M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101340 · Cited by 128
Synaptic Pruning by Microglia in Epilepsy
Andoh, M., Ikegaya, Y., & Koyama, R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122170 · Cited by 127
“Studies on microglia-dependent synapse elimination have mostly focused on excitatory synapses or have not distinguished between excitatory and inhibitory synapses [12,71,72].”
BackgroundPiirainen, S., Youssef, A. M., Song, C., Kalueff, A. V., Landreth, G. E., Malm, T., & Tian, L. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.046 · Cited by 136
“…soluble oligomers impaired LTP and purportedly promoted microgliaediated synaptic phagocytosis through interaction with the omplement system in a mouse AD model, suggesting that cogniive impairment due to microglia-mediated synaptic loss may well recede the A pathology in AD (Hong et al., 2016a).”
Cerovic, M., Forloni, G., & Balducci, C. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00284 · Cited by 128
Kummer, M. P., Ising, C., Kummer, C., Sarlus, H., Griep, A., Vieira‐Saecker, A., Schwartz, S., Halle, A., Brückner, M., Händler, K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108662 · Cited by 127
“…context, PD-1 not only regulates the inflammatory response mediated by inflammatory cytokines, e.g., IL-1 b , in AD (Heneka et al , 2013; Sheedy et al , 2013), but also modulates the complement system, which has recently been discussed to be critical for synaptic loss in AD (Hong et al , 2016).”
Geraghty, J. R., Davis, J. L., & Testai, F. D. (2019) · Neurocritical Care · doi:10.1007/s12028-019-00710-x · Cited by 140
Metadata
- Authors
- Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., Lemere, C. A., Selkoe, D. J., & Stevens, B.
- Affiliations
- Boston Children's Hospital (US)
- Brigham and Women's Hospital (US)
- University of California, San Francisco (US)
- Stanford Medicine (US)
- Broad Institute (US)
- Corresponding author
- Beja-Glasser, Victoria F.
- Nfonoyim, Bianca M.
- Stevens, Beth
- ORCID
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 712-716
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5094372
- OpenAlex
- W2314634699
- Cited by
- 3,343
- References
- 33
- Citations by year
- 2026: 415 · 2025: 391 · 2024: 384 · 2023: 388 · 2022: 324 · 2021: 363 · 2020: 306 · 2019: 260 · 2018: 240 · 2017: 198 · 2016: 69
- FWCI
- 140.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Edward R. and Anne G. Lefler Fellowship
- Coins for Alzheimer's Research Trust
- Fidelity Biosciences Research Initiative
- JPB Foundation
- National Institutes of Health (AG000222)
- National Institute of Neurological Disorders and Stroke-NIH (R01NS083845)
- National Institute on Aging-NIH (1RF1AG051496A)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- Alzheimer's disease, synaptic loss, complement system, microglia, C1q, CR3, complement C3, soluble amyloid-beta oligomers, neuroinflammation, synaptic pruning, hippocampal long-term potentiation, phagocytosis, mouse model
- MeSH terms
- Disks Large Homolog 4 Protein, Alzheimer Disease, Animals, Cognition Disorders, Complement Pathway, Classical, Disease Models, Animal, Membrane Proteins, Phagocytosis, Synapses, Up-Regulation, Complement C1q, Macrophage-1 Antigen, Amyloid beta-Peptides, Synaptophysin, Microglia, Long-Term Potentiation, Mice, Knockout, Mice, Guanylate Kinases, CA1 Region, Hippocampal, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.